- Foreword
- Advisory Board
- Introduction - CCT
- Training and Education
Provided by CCT
- SFDA Inspection and Accreditation
- Ethics Committee
- Central Laboratories
- Clinical Trials Capabilities
 Cardiology
 Clinical Oncology
 Digestive and
 Liver Diseases
 Endocrinology
   Ophthalmology
   Phase I Studies Unit
   Paediatrics
   Anaesthesia and
 Intensive Care
   Community and
 Family Medicine
   Neurology
   Orthopedic and
 Traumatology
   Psychiatry
   Rheumatology
   Surgery
 
 

Clinical Trials Capabilities > Cardiology

Strength and Expertise

Division of Cardiology is a pioneer in research projects in cardiovascular medicine and has gained international reputation :

  • Cardiac Resynchronization Therapy and other advanced device therapy for heart failure
  • Device monitoring for heart failure
  • Echocardiography
  • Endothelial dysfunction
  • Clinical research for cardiovascular diseases
  • Cardiac pacing and arrhythmia

Special Facility and Equipment

  • State of Art Echocardiography Machines (2 GE-Vivid 7, 1 hand-carried Vivid-I, 1 Philips IE33, Toshiba APLIO) plus other total 12 machines, including machines with capability of intracardiac echocardiography.
  • Non-contact Mapping System (Ensite) - St Jude Medical-Endocardial solution
  • Radiofrequency Ablation Console - EP Shuttle (Johnson & Johnson); EPT 1000Xp Radiofrequency Ablation Systems (Boston Scientific); CryoAblation System (Cryocath)
  • Intravascular Ultrasound System Boston Scientific Galaxy 2
  • Doppler Flow Mapping Huntleigh
  • Thrombectomy system Angiojet
  • Rotablator Console Rotablator (Boston Scientific)
  • SphymogCorTM Sphygmocardiography for pulse wave analysis

Disease Types and Number of Patients Potential for Clinical Trials Recruitment

  • Heart Failure: > 2,000
  • Hypertension: > 5,000
  • Acute Coronary Syndrome: > 1,000
  • Arrhythmia: > 1,000
  • Pacemaker and Follow up: > 1,700

Collaboration, Partners and Multi-centre Trials Capability

  • International Multicenter Studies - Principal and Leading Investigator:
    • Pace to Avoid Cardiac Enlargement (PACE study)
    • Medtronic Impedance Diagnostics in Heart Failure Patients (MIDHeFt study)
    • Validation of IEGM based Method Via TDI for optimization of Cardiac Resynchronization therapy in Heart Failure patients (IEGM-CRT)
    • 24 Hour Holter Evaluation of the St. Jude Medical, Research Concept: Far Field Signal Reduction, Bipolar Screw-In Pacing Lead
  • International Multicenter Studies - Steering Committee Member of International Multicenter Studies:
    • ONgoing Telmisartan Alone and in combinzation with Ramipril Global Endpoint Trial (ONTARGET) - National investigator representing Hong Kong for year 2002-2003
    • Telmisartan Randomised AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) - National investigator representing Hong Kong for year 2002-2003
    • Optimal Ventricular Resynchronization and BNP In Heart Failure Therapy (ORBIT)
    • Predictors Of Response to Cardiac Resynchronization Therapy (PROSPECT) – International steering committee and publication committee member
    • FAST – Extension study – Study to examine the clinical utility of impedance monitoring for heart failure patients implanted with biventricular-ICD
    • Diagnostic Outcome Trial in Heart Failure – DOT-HF
    • SENsitivity of the InSync SEntry Optival feature for the predication of Heart Failure - SENSE-HF
  • Centers of Excellence for Echocardiography Study by GE-Medical and Phillips
  • Collaboration with Mayo Clinic, USA for CUHK-Mayo Clinic-China Cardiovascular Summit 2007
  • SFDA Approved Center for Clinical Trials (since 1st August 2006)

 

Clinical Trials Monitored and/or Audited by Industry, FDA and local RGC etc.

  • Audited by Industry / Pharmaceutical Companies:
    • Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients - Boehringer Ingelheim (HK) Ltd.
    • Sensitivity of the InSyncTM OptiVolTM Feature for the Prediction of Heart Failure (SENSE-HF) – Medtronic
    • Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator. - Sanofi-Aventis
    • Fluid Accumulation Status Trial (FAST) – Medtronic
    • A placebo-controlled, double-blind, parallel arm trail to assess the efficacy of dronedarone 400mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation / atrial flutter CAF/AFL (ATHENA) - Sanofi-Aventis
    • IMPROVE-IT-Multicenter, Double-Blind, Randomized Study - Schering-Plough Research Institute
    • EARLY ACS. - Schering Plough Research Institute
    • Cardiac Contractility Modulation for the Treatment of Heart Failure - Impact of Haemodynamic Optimization of Lead Position - Impulse Dynamics
    • Pacing to Avoid Cardiac Enlargement (PACE) Study - Medtronic International ltd
    • APPROACH-A Phase III, 18-month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide - GlaxoSmithKline Limited
    • ACTIVE study - A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, with Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events in Patients with Atrial Fibrillation - Sanofi-Aventis
    • The Endeavor II Trial - A randomized controlled trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesion – Medtronic
  • Audited by Local RGC Grants – CERG:
    • Serial Echocardiographic Assessment of Early Right Ventricular Dysfunction by Tissue Doppler Echocardiography & its Impact on Left Ventricular Function – CERG (CUHK4475/06M)
    • Assessment of the Effect of Dual Chamber Pacing on Left Ventricular Diastolic Function in Patients With and Without Pre-existing Diastolic Dysfunction – CERG (448505)